Literature DB >> 20551462

Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain.

Ayesha Akbar1, Yiangos Yiangou, Paul Facer, W G Brydon, Julian R F Walters, Praveen Anand, Subrata Ghosh.   

Abstract

OBJECTIVE: Transient receptor potential vanilloid type 1 (TRPV1) has been shown to play an important role in visceral hypersensitivity. A significant proportion of patients with inflammatory bowel disease (IBD) continue to complain of abdominal pain despite their disease being otherwise quiescent. We investigated TRPV1-immunoreactive fibres in rectosigmoid biopsies taken from such patients with correlation to abdominal pain severity.
METHODS: Rectosigmoid biopsies were collected from 20 patients with quiescent IBD fulfilling Rome II criteria for irritable bowel syndrome (IBS), from 20 asymptomatic patients with quiescent IBD and from 28 controls. Abdominal pain scores were recorded using a validated questionnaire. TRPV1- and neuronal marker protein gene product 9.5 (PGP 9.5)-expressing nerve fibres, and lymphocytes (CD3 and CD4) were quantified, following immunohistochemistry with specific antibodies. The biopsy findings were related to abdominal pain scores.
RESULTS: A significant 3.9-fold increase in median number of TRPV1-immunoreactive fibres was found in biopsies from patients with quiescent IBD with IBS symptoms when compared with controls (p<0.0001) and a 5-fold increase when compared with the asymptomatic quiescent IBD group (p=0.0003). In the IBD with IBS symptoms group, the total nerve fibres (PGP 9.5) did not differ from those in the asymptomatic IBD group (p=0.10) or the control group (p=0.33) and neither did the CD3 lymphocyte (asymptomatic IBD group p=0.17; controls p=0.88) or CD4 lymphocyte (asymptomatic IBD group p=0.39; controls p=0.97) counts. In stepwise multivariate linear regression analysis, only TRPV1-immunoreactive nerve fibres (R(2)=0.8; p<0.0001) were significantly related to the abdominal pain score.
CONCLUSIONS: Increased TRPV1 nerve fibres are seen in quiescent IBD with IBS-like symptoms together with a correlation to pain severity. TRPV1 may contribute to the pathophysiology of ongoing pain and visceral hypersensitivity in this group of patients, providing a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551462     DOI: 10.1136/gut.2009.194449

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  52 in total

Review 1.  Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system.

Authors:  Peter Holzer
Journal:  Pharmacol Ther       Date:  2011-03-21       Impact factor: 12.310

2.  Adherent-Invasive E. coli enhances colonic hypersensitivity and P2X receptors expression during post-infectious period.

Authors:  Amandine Lashermes; Ludivine Boudieu; Julie Barbier; Benoit Sion; Agathe Gelot; Nicolas Barnich; Denis Ardid; Frédéric Antonio Carvalho
Journal:  Gut Microbes       Date:  2017-10-04

Review 3.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

Review 4.  IBS and IBD - separate entities or on a spectrum?

Authors:  Robin Spiller; Giles Major
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-26       Impact factor: 46.802

5.  Cross-talk between neural and immune receptors provides a potential mechanism of homeostatic regulation in the gut mucosa.

Authors:  B M Assas; J A Miyan; J L Pennock
Journal:  Mucosal Immunol       Date:  2014-09-03       Impact factor: 7.313

6.  Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction.

Authors:  Hai-Lian Shi; Chu-Hsuan Liu; Li-Li Ding; Yu Zheng; Xiao-Yan Fei; Lu Lu; Xue-Ming Zhou; Jian-Ye Yuan; Jian-Qun Xie
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

7.  Pain management in patients with inflammatory bowel disease: insights for the clinician.

Authors:  Arvind Iyengar Srinath; Chelsea Walter; Melissa C Newara; Eva M Szigethy
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

8.  Managing pain in inflammatory bowel disease.

Authors:  Michael J Docherty; R Carter W Jones; Mark S Wallace
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-09

Review 9.  Disorders of the enteric nervous system - a holistic view.

Authors:  Beate Niesler; Stefanie Kuerten; I Ekin Demir; Karl-Herbert Schäfer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-29       Impact factor: 46.802

10.  TRPM8 activation attenuates inflammatory responses in mouse models of colitis.

Authors:  Rithwik Ramachandran; Eric Hyun; Liena Zhao; Tamia K Lapointe; Kevin Chapman; Christina L Hirota; Subrata Ghosh; David D McKemy; Nathalie Vergnolle; Paul L Beck; Christophe Altier; Morley D Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.